Sarah Boyce

Advisor

Sarah Boyce is an advisor at Raven. Prior to joining Raven, Sarah Boyce served as President and Chief Executive Officer and as a member of the Board of Directors of Avidity Biosciences from October 2019 until its acquisition by Novartis. She has more than 25 years of global leadership experience at pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity was marked by transformative leadership, beginning with the company’s successful Series C financing and IPO. She drove the company’s evolution from a research and development organization to a biopharmaceutical company by advancing three rare neuromuscular disease therapies into clinical development and expanding the broad utility of the company’s RNA technology. Her tenure culminated in Novartis’s approximately $12 billion acquisition of Avidity for its neuroscience pipeline and differentiated RNA-delivery platform. Prior to joining Avidity, Sarah served as President and a member of the Board of Directors of Akcea Therapeutics. She previously held executive roles in business development and global operations at leading life sciences companies, including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology, and Roche. Sarah currently serves as Chair of the Board of Atrium Therapeutics and as a member of the Boards of Directors of Abcuro and Contineum Therapeutics.